Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy

  1. Gross, Sophia
  2. Ihlow, Jana ORCID logo
  3. Busack, Leonie
  4. Adamiak, Kacper
  5. Schrezenmeier, Jens
  6. Jesse, Julia
  7. Schwarz, Michaela
  8. Flörcken, Anne
  9. Vuong, Lam Giang
  10. Rieger, Kathrin
  11. Krönke, Jan ORCID logo
  12. le Coutre, Philipp
  13. Boldt, Vivien
  14. von Brünneck, Ann-Christin
  15. Horst, David
  16. Burmeister, Thomas ORCID logo
  17. Blau, Igor-Wolfgang
  18. Keller, Ulrich ORCID logo
  19. Bullinger, Lars ORCID logo
  20. Westermann, Jörg

Download
41408_2024_Article_1140.pdf 2,53MB
WeightNameValue
1000 Titel
  • Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy
1000 Autor/in
  1. Gross, Sophia |
  2. Ihlow, Jana |
  3. Busack, Leonie |
  4. Adamiak, Kacper |
  5. Schrezenmeier, Jens |
  6. Jesse, Julia |
  7. Schwarz, Michaela |
  8. Flörcken, Anne |
  9. Vuong, Lam Giang |
  10. Rieger, Kathrin |
  11. Krönke, Jan |
  12. le Coutre, Philipp |
  13. Boldt, Vivien |
  14. von Brünneck, Ann-Christin |
  15. Horst, David |
  16. Burmeister, Thomas |
  17. Blau, Igor-Wolfgang |
  18. Keller, Ulrich |
  19. Bullinger, Lars |
  20. Westermann, Jörg |
1000 Verlag Nature Publishing Group UK
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-09-16
1000 Erschienen in
1000 Quellenangabe
  • 14(1):160
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41408-024-01140-5 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11405931/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • <jats:title>Abstract</jats:title><jats:p>Therapy-related acute myeloid leukemia (t-AML) often exhibits adverse (genetic) features. There is ongoing discussion on the impact of t-AML on long-term outcome in AML. Therefore, we retrospectively analyzed clinical and biological characteristics of 1133 AML patients (225 t-AML patients and 908 de novo AML patients) with a median follow-up of 81.8 months. T-AML patients showed more adverse genetic alterations, higher age and more comorbidities as compared to de novo AML. Median OS in intensively treated t-AML patients was 13.7 months as compared to 39.4 months in de novo AML (<jats:italic>p</jats:italic> &lt; 0.001). With non-intensive therapy, OS did not differ significantly (<jats:italic>p</jats:italic> = 0.394). With intensive therapy, significant differences in favor of de novo AML were observed in the ELN intermediate I/II (<jats:italic>p</jats:italic> = 0.009) and adverse (<jats:italic>p</jats:italic> = 0.016) risk groups but not within favorable risk groups (APL <jats:italic>p</jats:italic> = 0.927, ELN favorable <jats:italic>p</jats:italic> = 0.714). However, t-AML was no independent risk factor for OS (<jats:italic>p</jats:italic> = 0.103), RR (<jats:italic>p</jats:italic> = 0.982) and NRM (<jats:italic>p</jats:italic> = 0.320) in the multivariate analysis. A limitation of our study is an ELN 2010 risk stratification due to a lack of more comprehensive molecular data according to ELN 2022. We conclude that therapeutic algorithms in t-AML, in particular with regard to allo-HSCT, should be guided by ELN genetic risk rather than classification as t-AML alone. Our data support the WHO and ICC 2022 classifications, which include t-AML as diagnostic qualifier rather than a separate subcategory.</jats:p>
1000 Sacherschließung
lokal Adolescent [MeSH]
lokal Female [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Aged, 80 and over [MeSH]
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Middle Aged [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/adverse effects [MeSH]
lokal Neoplasms, Second Primary/epidemiology [MeSH]
lokal /692/308/174
lokal Article
lokal Male [MeSH]
lokal /692/308
lokal Prognosis [MeSH]
lokal Young Adult [MeSH]
lokal Neoplasms, Second Primary/etiology [MeSH]
lokal Leukemia, Myeloid, Acute/therapy [MeSH]
lokal article
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/R3Jvc3MsIFNvcGhpYQ==|https://orcid.org/0000-0001-5484-1321|https://frl.publisso.de/adhoc/uri/QnVzYWNrLCBMZW9uaWU=|https://frl.publisso.de/adhoc/uri/QWRhbWlhaywgS2FjcGVy|https://frl.publisso.de/adhoc/uri/U2NocmV6ZW5tZWllciwgSmVucw==|https://frl.publisso.de/adhoc/uri/SmVzc2UsIEp1bGlh|https://frl.publisso.de/adhoc/uri/U2Nod2FyeiwgTWljaGFlbGE=|https://frl.publisso.de/adhoc/uri/RmzDtnJja2VuLCBBbm5l|https://frl.publisso.de/adhoc/uri/VnVvbmcsIExhbSBHaWFuZw==|https://frl.publisso.de/adhoc/uri/UmllZ2VyLCBLYXRocmlu|https://orcid.org/0000-0002-4649-0506|https://frl.publisso.de/adhoc/uri/bGUgQ291dHJlLCBQaGlsaXBw|https://frl.publisso.de/adhoc/uri/Qm9sZHQsIFZpdmllbg==|https://frl.publisso.de/adhoc/uri/dm9uIEJyw7xubmVjaywgQW5uLUNocmlzdGlu|https://frl.publisso.de/adhoc/uri/SG9yc3QsIERhdmlk|https://orcid.org/0000-0003-4843-2876|https://frl.publisso.de/adhoc/uri/QmxhdSwgSWdvci1Xb2xmZ2FuZw==|https://orcid.org/0000-0002-8485-1958|https://orcid.org/0000-0002-5890-5510|https://frl.publisso.de/adhoc/uri/V2VzdGVybWFubiwgSsO2cmc=
1000 Hinweis
  • DeepGreen-ID: 18f81fca6695457790e9472094fdc553 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6504967.rdf
1000 Erstellt am 2025-02-06T04:41:55.266+0100
1000 Erstellt von 322
1000 beschreibt frl:6504967
1000 Zuletzt bearbeitet 2025-09-13T13:07:17.302+0200
1000 Objekt bearb. Sat Sep 13 13:07:17 CEST 2025
1000 Vgl. frl:6504967
1000 Oai Id
  1. oai:frl.publisso.de:frl:6504967 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source